In its decision of 26 June 2009, the latter confirmed the patent office’s rejection of a patent for Glivec, denying “significantly enhanced efficacy” of Glivec under Article 3(d) over a previously known molecule (see the IPAB decision in Novartis AG v Union of India et al. Business Standard of 5 July 2009). In addition, the IPAB ruled that because of the price charged for Glivec, poor cancer patients in India would not be able to afford the drug, which in turn would threaten many people’s lives and thus create public disorder in the country (p. 191 of the decision).